NEW YORK, NY--(Marketwired - Aug 20, 2013) - Nuvilex, Inc. (
One would have to be sleeping under a rock to ever think Nuvilex isn't investing in its future. With last month's acquisition of exclusive, worldwide licenses associated with the live-cell encapsulation-based pancreatic cancer treatment, along with this month's announcement that the company will acquire licenses associated with the use of the live-cell encapsulation technology in developing treatments for diabetes, Nuvilex is making investments that could put it on the map in the biotech industry.
More importantly, these investments could have larger biotech and pharmaceutical companies lining up at Nuvilex's door to use the technology they will control for any type of cancer or diabetes treatment by any company or entity whatsoever that wants to use the unique and proprietary cellulose-based live-cell encapsulation as part of its treatment. Keep in mind that Nuvilex made a blockbuster deal to acquire the cancer assets it now owns for a paltry $1.5 million which gives the company total control over all treatments using the technology for any type of cancer.
So, with two successful Phase II trials in the books using the technology for the treatment of advanced, inoperable pancreatic cancer, Nuvilex is a Phase III trial away from possibly turning live-cell encapsulation-based treatments into a new wave of excitement and hope. Any company that has failed recently in its clinical trials to treat some form of cancer may want to replace that failed drug or treatment with Nuvilex's way of doing things. After all, in the biotech industry, it's about what's in your pipeline, and it's truly a "what have you done for me lately" business.
Both cancer and diabetes are multi-billion dollar industries. With the acquisitions that the Company has already made and will make in the near future, Nuvilex is preparing for future Phase III trials that need only show the same successes the technology has already demonstrated, and in doing so, the $1.5 million investment should make even Warren Buffet smile.
Read More Reports and Articles on Nuvilex, Inc. at www.stockmarketmediagroup.com/features/NVLX
About Stock Market Media Group
Stock Market Media Group is a full service Investment Relations firm specializing in Research and Content Development. It offers a platform for CEOs to tell their story through the media with Research Reports, CEO Interviews and Feature Articles while building a library of Research for Investors. For more information: www.stockmarketmediagroup.com
- Disease & Medical Conditions
- Warren Buffet
- pancreatic cancer
Stock Market Media Group